Sort
4,870 grants matching “glp 1”
Development of whole yeast-based hepatitis C vaccines and Immunotherapeutics
$290,373Richard C Duke · Globeimmune, Inc. · U01 · FY2007 · AI
Commercial and Regulatory Development of an Enhanced Performance Hemodialysis Access Graft
$290,351Andrew Marshall · Healionics Corporation · SB1 · FY2025 · HL
REPRESSIVE HISTONE AND DNA METHYLATION IN RODENT DEPRESSION MODELS
$290,192Eric J Nestler · Icahn School Of Medicine At Mount Sinai · P50 · FY2016 · MH
REPRESSIVE HISTONE AND DNA METHYLATION IN RODENT DEPRESSION MODELS
$290,192Eric J Nestler · Icahn School Of Medicine At Mount Sinai · P50 · FY2014 · MH
Impact of Neprilysin on Islet Function
$289,971Sakeneh Zraika · Seattle Inst For Biomedical/Clinical Res · R01 · FY2013 · DK
Network Pharmacology for Epilepsy Prevention
$289,890Pavel Klein · Prevep, Inc. · R43 · FY2021 · NS
Role of GLP-1 in Congenital Hyperinsulinism
$289,763Diva Del Carmen De Leon · Children'S Hosp Of Philadelphia · R56 · FY2010 · DK
Glucagon Biosynthesis and Metabolism
$289,335Joel F Habener · Massachusetts General Hospital · R01 · FY2008 · DK
Aminospectinomycin antibacterials for the treatment of antibiotic-resistant gonorrhea and other bacterial STDs
$289,030Michelle M. Butler · Microbiotix, Inc · R43 · FY2018 · AI
PROLIFERATIVE VS MEIOTIC FATE DECISION IN C. ELEGANS
$288,800Tim B. Schedl · Washington University · R01 · FY2014 · GM
PROLIFERATIVE VS MEIOTIC FATE DECISION IN C. ELEGANS
$288,800Tim B. Schedl · Washington University · R01 · FY2012 · GM
PROLIFERATIVE VS MEIOTIC FATE DECISION IN C. ELEGANS
$288,800Tim B. Schedl · Washington University · R01 · FY2015 · GM
Mechanisms of Intestinal Stem Cell Expansion Following Resection
$288,751Michael A Helmrath · Univ Of North Carolina Chapel Hill · R01 · FY2009 · DK
Mechanisms of alimentary chemosensation
$288,746Steven D Munger · University Of Maryland Baltimore · R01 · FY2013 · DC
ROLE OF PRESENILIN IN NOTCH AND APP MATURATION
$288,572Washington University · R01 · FY2003 · AG
DIET/GROWTH FACTOR MECHANISMS OF GUT ADAPTATION
$288,382Emory University · R01 · FY2002 · DK
Long lasting ghrelin derivatives for the treatment of cancer cachexia
$288,302Tarik Soliman · Extend Biosciences, Inc. · R43 · FY2013 · CA
Artificial Immune Moduating (AIM??)Platform for the Treatment of Cancer
$288,268Bruce J McCreedy · Neximmune, Inc. · R43 · FY2013 · CA
Preclinical Evaluation of a Novel Immunomodulatory Vaccine for Preventing and Treating HSV Infections
$288,088Edward Gershburg · Rational Vaccines, Inc. · R44 · FY2023 · AI
Pharmacokinetics and Subjective Responses to Alcohol After Bariatric Surgery
$287,215Marta Yanina Pepino De Gruev · University Of Illinois At Urbana-Champaign · R01 · FY2016 · AA
Pathology
$287,070Thomas March · Lovelace Biomedical & Environmental Research Institute · U54 · FY2008 · NS
CORE--MICROARRAY & ANALYSIS SHARED SERVICE
$286,657Michael John Becich · University Of Pittsburgh At Pittsburgh · P30 · FY2008 · CA
Biomarker Developmental Unit
$286,229Cecilia C Yeung · Fred Hutchinson Cancer Center · U2C · FY2025 · CA
Optimizing Stage 2 T1DM Management: Assessing the Impact of GLP-1Ra on Metabolic Outcomes in Patients Receiving Teplizumab
$285,975Daniel J. Moore · Vanderbilt University Medical Center · R01 · FY2025 · DK
FGF-2 mimetic peptides as pleuripotent mitigators of ARS and DEARE
$285,968Paul Okunieff · University Of Maryland Baltimore · U19 · FY2024 · AI